https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48960 Wed 13 Mar 2024 14:17:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30784 Wed 11 Apr 2018 13:21:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55064 Mon 08 Apr 2024 12:38:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32397 Mon 06 Feb 2023 11:55:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41780 Fri 12 Aug 2022 12:03:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45565 1.5-fold) with a confidence corresponding to false discovery rate (FDR) <1% in small-, medium-, and large-sized fibroid samples regardless of MED12 mutation status. The TNC was validated on additional patient samples using Western blotting (WB) and immunohistochemistry (IHC) and confirmed significant overexpression of this protein in fibroids compared to matched ANM. Proteomic analyses have identified the increased ECM protein expression, TNC, as a hallmark of uterine fibroids regardless of MED12 mutations. Further functional studies focusing on the upregulated ECM proteins in leiomyogenesis will lead to the identification of novel ECM drug targets for fibroid treatment.]]> Fri 04 Nov 2022 14:44:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47881 Fri 03 Feb 2023 15:52:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51354 Fri 01 Sep 2023 13:44:28 AEST ]]>